Fig. 5
From: Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Intranasal circRNA vaccine boosts adoptive transferred antigen-specific T cells for enhanced anti-tumor immune response. a Timeline of the experiment to evaluate the anti-tumor ability of combination therapy with intranasal circRNA vaccine and transferred OT-1 cells. b, c Bioluminescence images (b) and statistical result of average radiance (c) at different time points. Data were analyzed with two-way ANOVA with Tukey’s multiple comparisons test. d Representative images of HE staining to evaluate the tumor formation at day 21. Scare bar, 1250 μm (upper) or 200 μm (lower). e Representative plots of the transferred and endogenous antigen-specific T cells among different groups. f, g Statistical analysis of antigen-specific T cells in e. Data were analyzed by Student’s t test. h Scheme of the experiments to evaluate the role of endogenous T cells in killing antigen-loss tumor cells. Splenocytes were co-cultured with B16-luciferase cells (without OVA antigen) for IFN-γ Elispot assay. Splenocytes from the mice in the combination therapy group were transferred to Rag1−/− followed by B16-luciferase cells challenge. Created with BioRender.com. i Statistical results of the number of IFN-γ spots. Data were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. j Survival curve of the Rag1−/− mice, n = 6 for each group. Data were analyzed via Kaplan-Meier analysis. All data are represented as mean ± SEM
